pth 15.1, CCa 2.75 ? whats the next work up or what speciality to refer for patient inpatient in uk hospital
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
This gives a solid clinical framework. Now I have enough to provide a comprehensive answer.
PTH 15.1 pmol/L (low) + Corrected Ca 2.75 mmol/L (high)
What this pattern means
Suppressed PTH + elevated calcium = PTH-independent hypercalcaemia. This rules out primary hyperparathyroidism (where PTH would be elevated or inappropriately normal). The cause lies outside the parathyroid glands — most commonly malignancy or granulomatous disease.
Immediate Inpatient Workup
Bloods (urgent)
| Test | Rationale |
|---|---|
| PTHrP (PTH-related protein) | Most common mediator of humoral hypercalcaemia of malignancy (HHM) — produced by squamous, renal, breast, bladder tumours |
| Serum protein electrophoresis (SPEP) + serum free light chains | Rule out myeloma (often presents insidiously with hypercalcaemia) |
| Serum ACE + 1,25(OH)₂ vitamin D (calcitriol) | Elevated in sarcoidosis and other granulomatous diseases (TB, lymphoma) — granulomas hydroxylate 25-OH-D unregulated |
| 25-OH vitamin D | Rule out vitamin D toxicity |
| TFTs | Thyrotoxicosis can cause hypercalcaemia |
| Cortisol (9am) / short Synacthen | Addison's disease |
| FBC, film, ESR | Myeloma, haematological malignancy |
| LFTs, ALP | Bony metastases (raised ALP), hepatic involvement |
| U&E, eGFR | Renal impairment worsens hypercalcaemia |
| Urine Bence Jones protein / urine electrophoresis | Myeloma |
Urine
- 24-hour urine calcium/creatinine ratio — also helps exclude familial hypocalciuric hypercalcaemia (FHH) if needed
Imaging
| Modality | Purpose |
|---|---|
| CXR | Lung malignancy, sarcoid (hilar lymphadenopathy), TB |
| CT chest/abdomen/pelvis (if no obvious cause) | Occult malignancy screen — most productive first-line scan for HHM |
| Skeletal survey or whole-body low-dose CT | Myeloma lytic lesions |
| Bone scan (if bone mets suspected) | Osteolytic metastases |
Referral (UK Inpatient)
Given PTH-suppressed hypercalcaemia, this is not an endocrine/parathyroid problem as primary workup. The priority is:
- Haematology — if SPEP/light chains suggest myeloma (highly common cause of suppressed PTH + hypercalcaemia, especially age >50)
- Oncology — if PTHrP elevated or CT reveals occult solid tumour
- Respiratory/Chest Medicine — if sarcoidosis pattern (bilateral hilar adenopathy, elevated ACE, calcitriol)
- Endocrinology — if no malignancy/granuloma found, to evaluate rarer endocrine causes (Addison's, thyrotoxicosis, VIPoma) or if the picture remains unclear
In most UK hospitals, the medical registrar or acute medicine consultant would coordinate the above investigations and initiate the relevant specialist referral once the workup narrows the diagnosis.
Severity / Immediate Management
Ca 2.75 mmol/L is mild-moderate hypercalcaemia (≥3.0 is severe). If asymptomatic/stable:
- IV fluid resuscitation (0.9% NaCl) — first-line treatment regardless of cause
- Hold thiazide diuretics, lithium, calcium supplements, vitamin D supplements
- If myeloma or malignancy confirmed → bisphosphonate (zoledronic acid / pamidronate) + specialist input
Key question to answer first: Does the patient have a known malignancy? If yes, this is likely HHM or bony metastases — go straight to oncology. If no known cancer, myeloma screen and CT are the priority.
— Textbook of Family Medicine 9e, pp. 1056–1058; Brenner and Rector's The Kidney, 2-Volume Set
pth is high and so is calcium
So PTH 15.1 is actually high in your lab's reference range, and calcium 2.75 mmol/L is high. That changes everything.
PTH elevated + Calcium elevated = Primary Hyperparathyroidism (PHPT)
This is the classic pattern. An elevated (or even "inappropriately normal/high-normal") PTH in the context of hypercalcaemia is not physiologically appropriate — it should be suppressed. This points to autonomous PTH secretion from the parathyroid glands.
Immediate Inpatient Workup
Bloods
| Test | Rationale |
|---|---|
| Repeat corrected calcium | Confirm true hypercalcaemia |
| Phosphate | Low in PHPT (PTH promotes phosphaturia) |
| Magnesium | Hypomagnesaemia can cause secondary hyperparathyroidism |
| ALP | Elevated if significant bone turnover |
| Vitamin D (25-OH) | Deficiency can mask/worsen PHPT; needed before surgery |
| U&E / eGFR / creatinine | Renal involvement (nephrocalcinosis, stones) |
| Chloride | Hyperchloraemic acidosis seen in PHPT (Cl:phosphate ratio >33 suggestive) |
| 24-hour urine calcium | Critical — distinguishes PHPT from Familial Hypocalciuric Hypercalcaemia (FHH) (urine Ca very low in FHH) |
| Urine calcium:creatinine clearance ratio (CCCR) | CCCR <0.01 suggests FHH, not PHPT |
Imaging
| Modality | Purpose |
|---|---|
| Renal USS | Nephrolithiasis, nephrocalcinosis |
| DEXA scan | Bone mineral density — guides surgical decision |
If surgical candidacy being considered (Endocrine team will arrange):
- Sestamibi (Tc-99m) parathyroid scintigraphy — localises adenoma
- Neck USS (parathyroid) — first-line localisation
- 4D-CT neck — if USS/sestamibi discordant
Referral
→ Endocrinology is the primary referral for confirmed PHPT inpatient in a UK hospital.
They will:
- Confirm diagnosis and exclude FHH
- Assess for MEN syndrome (MEN1/MEN2A) if age <40, multi-gland disease, or family history — check prolactin, gastrin, fasting glucose, calcitonin
- Determine surgical candidacy and refer to Endocrine Surgery if criteria met
Surgical criteria (UK/NICE-aligned):
- Corrected Ca >2.85 mmol/L, or
- Age <50, or
- Renal stones / eGFR <60, or
- DEXA T-score < −2.5 at any site, or
- Symptomatic
At Ca 2.75 mmol/L, the patient is just below the automatic surgical threshold — Endocrinology will make the call based on full picture.
Immediate Management
- Ca 2.75 mmol/L is mild — IV fluids (0.9% NaCl) if symptomatic or dehydrated
- Avoid thiazides, calcium supplements, prolonged immobilisation
- Encourage oral hydration
- No bisphosphonates unless Ca climbs significantly
Bottom line: Refer to Endocrinology. Primary hyperparathyroidism until proven otherwise.
cinacalcet help?
Finding Sources
Reading File
Cinacalcet in Primary Hyperparathyroidism
Yes, it helps — but with important caveats.
Mechanism
Cinacalcet is a calcimimetic — it sensitises the calcium-sensing receptor (CaSR) on parathyroid cells to circulating calcium, tricking the gland into sensing higher calcium than is actually present. This reduces PTH secretion and brings serum calcium down.
What it does in PHPT
- Lowers serum calcium — effectively normalises Ca in most patients with long-term use
- Modestly reduces PTH — but does not normalise it
- Does NOT improve bone mineral density — unlike surgery
- Starting dose: 30 mg twice daily, titrated up to max 90 mg four times daily every 2–4 weeks
UK/Licensed indications for cinacalcet in PHPT
It is only approved for PHPT in the following situations:
- Unable to undergo parathyroidectomy (surgical risk, patient refusal, comorbidities)
- Inoperable parathyroid carcinoma with hypercalcaemia
- Secondary hyperparathyroidism in dialysis patients (separate indication)
For this patient (Ca 2.75 mmol/L, PHPT)
At this calcium level, cinacalcet is not first-line — the patient is below the automatic surgical threshold (2.85 mmol/L). Options in order:
| Approach | Indication |
|---|---|
| Parathyroidectomy | Preferred if surgical criteria met — only cure |
| Cinacalcet | If surgery declined or not fit — lowers Ca, not BMD |
| Cinacalcet + alendronate | If both hypercalcaemia and bone loss are concerns |
| Bisphosphonates alone | If goal is bone protection only (no effect on Ca or PTH) |
Practical point
In a UK inpatient setting, Endocrinology would initiate cinacalcet — it is not typically started by the acute team. If surgery is being considered, localisation imaging (parathyroid USS + sestamibi) takes priority over medical management.
Bottom line: Cinacalcet works for the calcium but doesn't fix the underlying disease or protect bone. Surgery is the only cure — cinacalcet is the bridge for those who can't or won't have it.
— Goldman-Cecil Medicine, Medical Therapy section
causes of hyperparthyroidsim
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Here is a structured breakdown of the causes of hyperparathyroidism across all three types:
Causes of Hyperparathyroidism
🔴 Primary Hyperparathyroidism (PTH high, Ca high)
Autonomous, inappropriate PTH secretion from the parathyroid glands themselves.
| Cause | Frequency |
|---|---|
| Solitary parathyroid adenoma | ~80% |
| Multiple adenomas | ~2–4% |
| Parathyroid hyperplasia (all 4 glands) | ~15% |
| Parathyroid carcinoma | <1% |
Familial/Syndromic causes (~10% of PHPT):
- MEN1 — parathyroid hyperplasia + pituitary tumour + pancreatic tumour (gastrinoma, insulinoma)
- MEN2A — parathyroid hyperplasia + medullary thyroid cancer + phaeochromocytoma
- MEN4 — similar to MEN1, CDC73/GCM2 mutations
- Hyperparathyroidism-jaw tumour syndrome — parathyroid tumours (up to 15% malignant) + ossifying jaw fibromas; CDC73 gene mutation
- Familial isolated hyperparathyroidism — MEN1, CaSR, GCM2 mutations
Radiation history to the neck is a recognised risk factor for sporadic adenoma.
🟡 Secondary Hyperparathyroidism (PTH high, Ca low/normal)
A physiological response to chronically low calcium — the parathyroids are working correctly but overdriven. By definition, cannot cause hypercalcaemia.
| Cause | Mechanism |
|---|---|
| Chronic kidney disease (CKD) | Phosphate retention → low Ca, reduced 1,25-OH vitamin D production |
| Vitamin D deficiency | Reduced gut Ca absorption → low Ca |
| Malabsorption (coeliac, Crohn's, bariatric surgery) | Poor Ca/vitamin D absorption |
| Osteomalacia/rickets | Mineralisation defect → low Ca |
| Pseudohypoparathyroidism | PTH resistance → high PTH despite adequate Ca |
🟠 Tertiary Hyperparathyroidism (PTH high, Ca high)
Long-standing secondary HPT causes the hyperplastic parathyroid tissue to become autonomously active — it no longer responds to calcium feedback. Seen in:
- End-stage renal disease / post-renal transplant — most common setting
- Persistent HPT after the original stimulus (e.g. CKD) has been corrected
Clinically resembles primary HPT biochemically but the history distinguishes it.
Quick Comparison
| Type | PTH | Calcium | Phosphate | Context |
|---|---|---|---|---|
| Primary | ↑ | ↑ | ↓ | Adenoma/hyperplasia |
| Secondary | ↑↑ | ↓ or normal | ↑ (in CKD) | CKD, vit D deficiency |
| Tertiary | ↑↑ | ↑ | Variable | Long-standing CKD/post-transplant |
For this patient (PTH high + Ca 2.75 mmol/L), the context (presumably no CKD or dialysis history) points to primary hyperparathyroidism, most likely a solitary adenoma — the cause in 80% of cases.
— Goldman-Cecil Medicine, 2 Vol. Set; Textbook of Family Medicine 9e
This is a shared conversation. Sign in to Orris to start your own chat.